Adenosine A3 receptor agonists
Details for Australian Patent Application No. 2002327426 (hide)
International Classifications
Event Publications
23 January 2003 Complete Application Filed
Priority application(s): 60/311,069 08.08.01 US
19 June 2003 Application Open to Public Inspection
Published as AU-B-2002327426
14 June 2007 Application Accepted
Published as AU-B-2002327426
18 October 2007 Application for Amendment
The nature of the amendment is as shown in the statement(s) filed 25 Sep 2007. Address for service in Australia - Freehills Patent & Trade Mark Attorneys Level 43 101 Collins Street Melbourne VIC 3000
18 October 2007 Standard Patent Sealed
15 October 2009 Amendment Made
The nature of the amendment is: Amend the patentee name from CV Therapeutics, Inc. to Gilead Palo Alto, Inc.
3 March 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired
This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
2002327427-Erythrocytic cells and method for preserving cells
2002327425-Compositions and methods for generating chimeric heteromultimers
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
- Editable Word format reports
- For IP Professionals
- Multiuser